CY1106146T1 - Μεθοδος προσδιορισμου της αρχικης δοσης ενωσεων βιταμινης d - Google Patents

Μεθοδος προσδιορισμου της αρχικης δοσης ενωσεων βιταμινης d

Info

Publication number
CY1106146T1
CY1106146T1 CY20061101187T CY061101187T CY1106146T1 CY 1106146 T1 CY1106146 T1 CY 1106146T1 CY 20061101187 T CY20061101187 T CY 20061101187T CY 061101187 T CY061101187 T CY 061101187T CY 1106146 T1 CY1106146 T1 CY 1106146T1
Authority
CY
Cyprus
Prior art keywords
vitamin
compounds
determining
initial dose
dose
Prior art date
Application number
CY20061101187T
Other languages
English (en)
Inventor
Michael J. Amdahl
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1106146T1 publication Critical patent/CY1106146T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρέχεται μέθοδος προσδιορισμού της αρχικής ή εναρκτικής δόσης ενώσεων βιταμίνης D όταν χρησιμοποιούνται για τη θεραπεία νεφρικής οστεοδυστροφίας ή δευτερογενούς υπερπαραθυρεοειδισμού. Η δόση έναρξης βασίζεται εν μέρει στην βασική γραμμή ΡΤΗ του ασθενούς. Η εφεύρεση επίσης παρέχει τη χορήγηση μιας αρχικής δόσης μιας ένωσης βιταμίνης D, όπου η δόση προσδιορίζεται ακολουθώντας τη μέθοδο της εφεύρεσης.
CY20061101187T 2000-10-13 2006-08-24 Μεθοδος προσδιορισμου της αρχικης δοσης ενωσεων βιταμινης d CY1106146T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24012600P 2000-10-13 2000-10-13
PCT/US2001/042708 WO2002031514A2 (en) 2000-10-13 2001-10-12 A method of determining the initial dose of vitamin d compounds

Publications (1)

Publication Number Publication Date
CY1106146T1 true CY1106146T1 (el) 2011-06-08

Family

ID=22905214

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101187T CY1106146T1 (el) 2000-10-13 2006-08-24 Μεθοδος προσδιορισμου της αρχικης δοσης ενωσεων βιταμινης d

Country Status (12)

Country Link
US (1) US20030092686A1 (el)
EP (1) EP1334367B1 (el)
JP (1) JP2004532801A (el)
AT (1) ATE329268T1 (el)
AU (2) AU2002213483B2 (el)
CA (1) CA2423316A1 (el)
CY (1) CY1106146T1 (el)
DE (1) DE60120458T2 (el)
DK (1) DK1334367T3 (el)
ES (1) ES2266276T3 (el)
PT (1) PT1334367E (el)
WO (1) WO2002031514A2 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6066091A (en) * 1998-02-23 2000-05-23 North Carolina State University Methods, systems and products for determining drug withdrawal intervals

Also Published As

Publication number Publication date
ATE329268T1 (de) 2006-06-15
DE60120458T2 (de) 2007-01-11
DE60120458D1 (de) 2006-07-20
EP1334367A2 (en) 2003-08-13
CA2423316A1 (en) 2002-04-18
JP2004532801A (ja) 2004-10-28
WO2002031514A2 (en) 2002-04-18
DK1334367T3 (da) 2006-10-09
PT1334367E (pt) 2006-10-31
US20030092686A1 (en) 2003-05-15
AU1348302A (en) 2002-04-22
AU2002213483B2 (en) 2007-03-29
EP1334367B1 (en) 2006-06-07
ES2266276T3 (es) 2007-03-01
WO2002031514A3 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
BRPI0412684A (pt) compostos ppar-ativos
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1107506T1 (el) Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης
ATE308341T1 (de) Pharmazeutische formulierungen
ES2158108T3 (es) Vacunacion in ovo contra la coccidiosis.
ES2134051T3 (es) Procedimiento para la preparacion de sildenafil.
BR0109703A (pt) Derivados de piperazina
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
EA200101046A1 (ru) Производные индигоидных бис-индолов
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
HN2001000277A (es) PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1106146T1 (el) Μεθοδος προσδιορισμου της αρχικης δοσης ενωσεων βιταμινης d
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
DK1813272T3 (da) Veterinær anvendelse af et pleuromutilinderivat